Peptides Research Hub

Clinical Trial Identifier

NCT01179048

Liraglutide, part of the LEADER program.

Trial details

Identifier
NCT01179048
Sponsor
Novo Nordisk
Asset
Liraglutide
Program
LEADER
Phase
Phase III
Therapeutic area
Cardiovascular

Program context

LEADER

13% relative reduction in the three-component MACE composite (CV death, non-fatal MI, non-fatal stroke) with liraglutide versus placebo over a median follow-up of 3.8 years; hazard ratio 0.87 (95% CI 0.78 to 0.97). The cardiovascular death component drove the overall result.

Read the LEADER spotlight

Trial-level analysis lives in the program spotlight linked above. For the canonical registry record, including study design, eligibility, locations, and posted results, visit ClinicalTrials.gov.